Diabetes Complications Clinical Trials
People with diabetes are at higher risk for health issues like chronic kidney disease, diabetic macular edema, and liver disease. Here are clinical trials studying ways to treat diabetes-related complications.
Taking care of diabetes can be stressful, especially when it comes to the many complications that can result from years of high blood sugar levels.
Researchers are investigating a wide variety of medications to help alleviate complications, from drugs that have already been approved for glycemic control to new investigational therapies.
Here are several trials specifically focused on diabetes complications:
This trial is investigating a new oral medication, INV-202, which is designed to improve regulation in the kidney, liver, and pancreas in people with type 1 or type 2 diabetes.
Join a study at the UC San Diego investigating the potential benefits of the GLP-1 agonist semaglutide for non-alcoholic fatty liver disease.
A clinical trial is recruiting participants with type 2 diabetes and chronic kidney disease (CKD) to see how well a combination of glucose-lowering and kidney-protective drugs works to slow the progression of CKD.
Beginning in March 2024, the FINE-ONE trial will investigate the effectiveness of Kerendia (finerenone), a medication to prevent kidney disease progression in adults with type 1 diabetes.
More clinical trials to watch out for:
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (REMODEL): Researchers are recruiting participants with type 2 diabetes and kidney disease for a year-long study investigating how Wegovy (semaglutide) works to fight CKD.
4D-150 in Patients With Diabetic Macular Edema: This study will compare the safety and efficacy of an experimental medication, 4D-150, to the well-established injection Eylea (aflibercept) among adults with diabetic macular edema due to type 1 or type 2 diabetes.
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (ESSENCE): This five-year trial will compare how well semaglutide helps treat NASH, examining various measures of liver function as well as body weight, inflammation, and other markers of cardiometabolic health.
Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (IMPACT Trial): This study is investigating how well the dual glucagon/GLP-1 receptor agonist pemvidutide helps treat NASH.
Learn more about diabetes complications here: